The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has launched a review of avacopan, a medicine used to treat rare autoimmune diseases that affect small blood vessels, after questions were raised about the integrity and reliability of data from the key clinical study that supported its approval.
The review has attracted attention within the medical community because avacopan plays an important role in the treatment of serious autoimmune conditions, and any reassessment of the evidence behind its approval could have implications for healthcare professionals and patients currently using the medicine.
According to the MHRA, the review was triggered by information that has raised concerns about the reliability of data from the pivotal clinical trial that formed the foundation of the medicine’s licence approval. Regulators are now examining whether those concerns alter the conclusions previously reached about the drug’s effectiveness and whether the overall balance between its benefits and risks remains favourable.
Avacopan, marketed as Avacopan Vifor and previously known as Tavneos, is approved for use alongside rituximab or cyclophosphamide in the treatment of adults with severe and active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). These are rare autoimmune diseases that cause inflammation and damage to small blood vessels throughout the body and can lead to serious complications if left untreated.
For patients living with these conditions, treatment options are often limited, making regulatory reviews of approved medicines particularly significant. While the MHRA has not concluded that the medicine is ineffective or unsafe, the agency says it is carefully reassessing the evidence that supported its original approval to determine whether the current licence remains justified.
The review is being conducted under Section 68 of the Human Medicines Regulations 2012. Under these regulations, the MHRA has the authority to revoke, suspend, or vary a medicine’s marketing authorisation if it determines that information submitted during the approval process is incorrect or no longer supports a positive balance between benefits and risks.
At this stage, the medicine remains available and healthcare professionals have not been instructed to stop prescribing it. The MHRA has emphasised that the existing safety recommendations contained in the product information remain in place while the review continues.
These measures include regular monitoring of liver function, monitoring white blood cell counts, and careful assessment of patients for signs of serious infections. Healthcare professionals are also being reminded to consider the individual risks and benefits of treatment when deciding whether avacopan remains appropriate for each patient.
The agency has issued a clear message to patients currently receiving avacopan treatment. Individuals taking the medicine should not stop treatment on their own or make changes to their medication without first consulting their doctor, specialist, or healthcare team.
For patients managing rare autoimmune diseases, sudden interruption of treatment could potentially worsen disease activity or create additional health complications. Medical experts therefore advise that any concerns about ongoing treatment should be discussed with healthcare professionals who can provide guidance based on individual circumstances.
The review highlights the important role regulators play in continuously monitoring medicines even after they have been approved for use. Drug approvals are based on clinical evidence available at the time, but regulators continue to assess new information that emerges after medicines enter routine clinical practice. When questions arise regarding safety, effectiveness, or the reliability of supporting evidence, authorities can reopen assessments to ensure patients continue to receive treatments that meet the required standards.
The MHRA has stated that the outcome of the review will be communicated once the assessment is complete. Depending on the findings, the regulator could decide that no changes are needed, introduce new warnings or restrictions, amend prescribing information, or take further regulatory action if necessary.
For now, healthcare professionals are being encouraged to remain vigilant and continue following existing monitoring requirements, while patients are advised to maintain regular communication with their healthcare teams and report any concerns or suspected side effects.
The MHRA also reminds healthcare professionals and members of the public that suspected adverse reactions to medicines can be reported through the Yellow Card Scheme, which helps regulators monitor the safety of medicines used across the UK.
As the review progresses, patients, clinicians, and healthcare organisations will be watching closely for further updates regarding the future use of avacopan and what the findings may mean for the treatment of rare autoimmune blood vessel diseases in the United Kingdom.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Patients taking avacopan or any other prescribed medication should consult their healthcare professional before making any changes to their treatment plan.